ArticleJournal of diabetes science and technology2026
Performance of a 15-Day Continuous Glucose Monitoring System in Children and Adolescents With Diabetes.
Article in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe CareSens Air (CSAir) continuous glucose monitoring system is approved for use in adults in South Korea and received adults-only CE marking in early 2024. The aim of this prospective, multicenter, pivotal study in children and adolescents with insulin-dependent diabetes mellitus was to determine if the performance and safety of CSAir in these populations are comparable to those observed in adults.
methodSensors were worn for 15 days on the upper arm in children and adolescents aged 7 to 17 years and on the upper arm and/or upper buttock in children aged 2 to 6 years. Frequent capillary comparator measurements were performed during in-clinic sessions at the beginning, middle, and end of the sensor-wearing period. Point accuracy was assessed via agreement rates (AR) and mean absolute relative difference (MARD). Additional assessments included clinical point accuracy, technical reliability, and safety.
resultsFor subjects aged 7 to 17 years, %20/20 AR was 90.8%, and MARD was 8.9%. A total of 99.9% of values fell within Zones A and B of the Diabetes Technology Society error grid. Sensor survival probability reached 75.2%. In children aged 2 to 6 years, %20/20 ARs were 86.6% and 98.4%, and MARDs were 10.3% and 7.8% for arm- and buttock-worn sensors, respectively. No serious adverse events were reported. Mild and moderate adverse device effects comprised skin issues such as itching or erythema at the sensor application or insertion site.
conclusionsThe observed performance and safety of CSAir in children and adolescents are similar to those in adults. These data may support an extension of regulatory approval of CSAir for children aged 2 years and older.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.